- Conditions
- Hemorrhage
- Interventions
- Kcentra®, Plasma
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Oakland, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Factor X Deficiency
- Interventions
- Human Coagulation FACTOR X
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Indianapolis, Indiana • New York, New York
- Conditions
- Traumatic Injury
- Interventions
- BE1116, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
- Conditions
- Significant Bleeding Risk
- Interventions
- Octaplex, Beriplex P/N (Kcentra)
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
- Conditions
- Cerebral Aneurysm Unruptured, Cerebral Aneurysm Ruptured
- Interventions
- Active SRP cases, Control cases
- Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, FEIBA, rFVIIa
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia A
- Interventions
- Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Factor X Deficiency
- Interventions
- FACTOR X
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Factor 10 Deficiency
- Interventions
- Coagadex
- Drug
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • New Orleans, Louisiana • Kalamazoo, Michigan
- Conditions
- Factor VIII Deficiency, Congenital
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- 5 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Haemophilic Pseudotumour
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Bleeding
- Interventions
- 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cardiopulmonary Bypass
- Interventions
- Recombinant activated factor VII, Prothrombin Complex Concentrate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Surgery
- Interventions
- andexanet alfa
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 15 more